“Growing Adoption of Monoclonal Antibodies & Long-Acting Therapies for Cholesterol Management”
- One prominent trend in the PCSK9 inhibitors market is the increasing adoption of monoclonal antibody-based therapies, such as evolocumab and alirocumab, due to their strong efficacy and safety profiles
- These biologics offer substantial LDL cholesterol reduction, especially for patients with familial hypercholesterolemia or those who are statin-intolerant, improving cardiovascular outcomes
- For instance, evolocumab has shown sustained LDL-C reductions of over 60% in clinical trials, and its long-acting dosing regimen (biweekly or monthly) enhances patient adherence and convenience
- This trend is driving the shift toward personalized cholesterol management, accelerating the development and uptake of next-generation PCSK9 inhibitors and expanding the market across high-risk patient populations
